Bullish Case: PACB at $1.38 with a backwardated term structure: near-dated IV is highest into Aug–Sep (uncertainty ahead of Aug 5 earnings) then eases. The PACB return-surface brightest bands cluster near modest cumulative moves (about −10% to +15%). My Helium point call (+3.5%) has weak historical linkage (corr −0.1), but earlier bearish-to-$~1.1 timing didn’t fully play out (−11.5% vs my −25%..−40%). If Aug 5 guidance shows no dilution shock, ~$1.60–$1.90 is plausible.

Bearish Case: SPY’s vol surface shows persistent downside skew (higher IV on lower strikes) out ~150 days, a macro channel that can amplify biotech drawdowns. PACB’s backwardated term structure keeps a near-term IV hump into Aug 22, consistent with an earnings-driven repricing risk. Earlier “continued collapse” wasn’t as severe as −25%..−40%, but it still left downside pockets on the return-surface relevant. If Aug 5 revenue/EPS or cash-runway deteriorate, downside weight increases toward −25% to −50% (~$0.70–$1.00); falsifiable via rising Sep/Dec put IV and dilution/financing headlines.

Potential Outcomes:

1. 30%: −5..+8 ($1.31–$1.49) if Aug-5 results near-consensus; PACB IV mean-reverts.
2. 25%: −25..−40 ($0.83–$1.04) if cash-runway/dilution concern grows; Sep put IV remains elevated.
3. 20%: +20..+35 ($1.66–$1.86) if consumables/HiFi scaling beats; near-dated call IV falls.
4. 15%: +60%+ ($2.20+) on material partnership/acquisition by Dec (8‑K/LOI).
5. 10%: −50% (~$0.70–$0.75) on equity offering/going‑concern warning by Dec.

July 23, 2026